Clonal replacement of tumor-specific T cells following PD-1 blockade
2019 · Nature Medicine · 1,488 citations
https://doi.org/10.1038/s41591-019-0522-3
K
Katherine McNamara
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
24
Papers
2.0K
Citations
8
h-index
7
i10-index
Katherine McNamara is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer Genomics and Diagnostics & HER2/EGFR in Cancer Research & Gene expression and cancer classification. The author has an h-index of 8, co-authored 21 publications.
ORCID: 0000-0002-3717-6494Papers by this author
worksPathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
2020 · Nature Communications · 65 citations
https://doi.org/10.1038/s41467-020-19494-2
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
2019 · Nature Communications · 60 citations
https://doi.org/10.1038/s41467-019-08593-4
Transcriptome and genome evolution during HER2-amplified breast neoplasia
2021 · Breast Cancer Research · 5 citations
https://doi.org/10.1186/s13058-021-01451-6
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
2019 · Nature Communications · 1 citations
https://doi.org/10.1038/s41467-019-10456-x
Additional file 2 of Transcriptome and genome evolution during HER2-amplified breast neoplasia
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14992939
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat